Introduction
Cytogenetic abnormalities have proven to be the most important predictor of clinical behavior in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). 1, 2 It is well known that AML patients with translocation (8;21)(q22;q22) or inversion 16(p13;q22) typically do well after treatment with cytarabine. [3] [4] [5] [6] [7] [8] Patients with normal karyotype may have undetected cytogenetic abnormalities that could alter their outcome. Conventional cytogenetic analysis is limited since only cells dividing in culture are analyzed, therefore these results may not be representative of the total population. Furthermore, G-banding can only detect gross chromosomal abnormalities and not abnormalities such as point mutations or deletions. Several molecular techniques are now available to detect more subtle chromosomal abnormalities. However, the clinical relevance of these molecular abnormalities detected in the absence of classical cytogenetic aberrations is unknown. The incidence of cytogenetically detected t(8;21) and inv (16) in patients with AML is about 6-8% and 3-7%, respectively. 9, 10 The molecular counterparts of these chromosomal changes have been identified: the fusion genes of the t(8;21) and inv (16) While the clinical significance of the presence of t(8;21) or inv(16) is well established, the presence of AML1/ETO and CBF␤/MYH11 in the absence of the typical cytogenetic abnormalities in de novo AML is not known. It is also not certain whether the molecular techniques should be used to screen all patients with AML or myelodysplastic syndrome to identify a subgroup who are more likely to have a favorable clinical response and outcome. To understand more about this, we conducted a study that examined the clinical outcome of patients with normal-karyotype de novo AML and RT-PCR positive for AML1/ETO vs the clinical outcome in patients shown to express t(8;21) by SC studies.
Materials and methods

Patients
From March 1997 to March 1998, we used RT-PCR to screen 104 patients with de novo AML or myelodysplastic syndrome without cytogenetic evidence of t(8;21) or inv(16) for molecular evidence of those abnormalities (standard cytogenetic testing at MD Anderson Cancer Center includes a minimum of 20 metaphases). Diagnosis and classification was based on the French-American-British (FAB) criteria. Flow cytometry studies and cytochemical staining were performed on all samples. Three patients with t(8;21) and three patients with inv (16) shown by SC were used as controls for RT-PCR analysis. Samples were collected from bone marrow or peripheral blood for RNA extraction, cDNA synthesis, nested RT-PCR for t(8;21) and inv (16) 
Reverse transcription/polymerase chain reaction
Total RNA was isolated using Trizol reagent (GIBCO BRL, Paisley, UK) according to the manufacturer's procedure. The following primers are used for the reverse transcription reaction and PCR: 5′-CAC TGT GAT GGC TGG CAA TG-3′ (AML1 outer primer), 5′-CCA CCT ACC ACA GAG CCA TC-3′ (AML1 inner primer), 5′-TGT AGG AGA ATG GCT CGT GC-3′ (ETO outer primer), 5′-TTG CGT CTT CAC ATC CAC AG-3′ (ETO inner primer), 5′-AAA TGA GGT CCT GCC ATC TG-3′ (intact AML transcript-control), 5′-CTC TTC TCA TTC TGC TC-3′ (inv(16) M1 inner primer), 5′-GCA GGC AAG GTA TAT TTG AAG G-3′ (inv(16) C1 inner primer), 5′-TTG GAG ATC CCT TTC GAA CTG G-5′ (MYH11 outer primer), and 5′-TGA AGA TAG AGA CAG GTC TCA T-3′ (CBF-␤ outer primer). 15, 16 The RNA was preserved at −20°C. First-strand cDNA for each of the RNAs of interest was synthesized from the RNA. About 2 g of RNA was mixed with 1.25 l of appropriate primer (0.4 g/l) or control to a total volume of 10 l. The mixture was then incubated at 90°C for 10 min and transferred to ice for at least 5 min. After adding a mixture of 4 l of 5× reverse transcription buffer, 2 l of 25 mM MgCl 2 , 1 l of 10 mM dNTPs, and 2 l of 1 mM DTT, the mixture was incubated for 5 min at 42°C. Next, 1 l of reverse transcriptase (200 units/l) was added to the mixture. After incubating for 1 h at 42°C, the reaction was terminated by a 15 min incubation at 70°C. Then the mixture was chilled on ice before adding 1 l of Rnase-H and incubated for 15 min at 37°C. The first-strand cDNA we obtained was used for the first round of PCR.
In a volume of 25 l, 2.5 l of the first-strand cDNA mixture was added to a mixture containing 1× PCR buffer, 1.5 mM of MgCl 2 , 1 mM dNTPs, 100 nM concentrations of each primer, and 2.5 units of Taq polymerase (Perkin Elmer, Norwalk, CT, USA). Samples were subjected to one cycle at 94°C for 4 min, then to 10 cycles at 92°C for 1 min, 60°C for 1 min, and 72°C for 1 min. This was followed by 30 cycles at 90°C for 1 min, 57°C for 1 min, 70°C for 1 min and a final extension at 72°C for 7 min. The second round of nested PCR was carried out under the same conditions using 2.5 l of the first-round PCR product as the template, and a 100 nM concentration of an appropriate primer pair. The RT-PCR products were visualized on a 2% agarose gel with ethidium bromide staining.
Positive controls included samples that were positive for t(8;21) and inv (16) as shown by SC analysis and PCR. The negative control was the PCR mixture without cDNA. The AML1 was used as an internal control. All cDNA samples were subjected to PCR to detect expression of the AML1 gene and thereby assess cDNA quality and the efficiency of the reverse transcriptase. If a discrepancy occurred with the control samples, the result was considered invalid and the PCR repeated. The PCR was performed independently by two blinded individuals. Each one repeated the PCR in all 110 patients at least twice to confirm the results. There was 100% concordance between the two observers.
Protein extraction and Western blot analysis for AML1/ETO fusion protein
Mononuclear cells from bone marrow samples were homogenized in ice-cold buffer (20 mM Tris/HCl, pH 7.2; 1 mM EDTA; 1 mM EGTA; 0.1 mM NaCl; 1 mM phenyl-methyl-sulfonyl-fluoride; and 0.1% aprotinin, 0.1% leupeptin, 0.1% pepstatin, and 0.1% Triton X-100). After solubilization on ice for 1 h, the lysate was centrifuged at 35 000 r.p.m. for 45 min, and the supernatant was collected. The protein concentration was estimated by standard assay (Bio-Rad Labs, Richmond, CA, USA), and 200 g of each extract was run on 7.5% sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and stained with Coomassie blue R-250 to check the protein profile.
For immunoblast analysis of the AML1 protein, 300 g of cell extract from various samples and normal bone marrow was electrophoretically separated on a 9.5% SDS-PAGE gel. The protein was then transferred to nitrocellulose paper. The nitrocellulose membranes were blocked with 5% nonfat milk in phosphate-buffered saline (PBS) containing 0.1% Tween 20 and 0.01% sodium azide for 6-8 h at room temperature. The blot was then incubated overnight at 4°C with rabbit anti-AML1 polyclonal antibody in a 1:500 dilution in PBS containing 2.5% nonfat milk, 2.5% bovine serum albumin, and 0.1% 
FISH studies
The FISH method is described in detail elsewhere. 17 FISH was carried out using a cocktail of biotinylated DNA probes for whole-chromosomes 8 and 21 (Oncor, Gaithersburg, MD, USA) labeled with digoxigenin.
Clinical data and statistical analysis
Clinical data were collected to compare patients showing an AML1/ETO molecular change with patients from MD Anderson Cancer Center who had t(8;21) detected by conventional cytogenetic methods. At least two metaphases had to show t(8;21) to be considered to have cytogenetic t(8;21). All patients included in the outcome analysis were treated with regimens containing HDAC. All patients were included on protocol studies, and the dose of cytarabine varied (1.5 mg/m 2 /day for 3 days, 1 g/m 2 /day for 5 days or 2 g/m 2 /day for 4 days). Findings in both groups of patients were compared using Fisher's exact test or the Kruskal-Wallis test. Survivals were estimated using the Kaplan-Meier method and compared with the log-rank test. 18 
Results
Detection of AML1/ETO fusion mRNA
RT-PCR was positive for the AML1/ETO fusion transcript in eight of the 104 patients (7.7%) without evidence of t(8;21) on SC analysis (Table 1 ). Five of these eight patients had a normal karyotype and one had insufficient metaphases. The rate of RT-PCR positivity was 5/54 in patients with a normal karyotype. One of the eight patients with a masked t(8;21) had a single metaphase showing t(8;21) on conventional testing. This is insufficient to establish a diagnosis. No instances of masked inv (16) were identified. Figure 1 shows an example of the RT-PCR results. 
Figure 1
Representative example of results of RT-PCR and amplification of AML1/ETO (A/E) and CBF␤/MYH11 (C/M) fusion transcript from three patients. The AML1 (A) gene transcript was used as a control to confirm viability of the RNA. In each experiment, reagents without template were used as a negative control.
Detection of AML1/ETO fusion protein
To confirm the RT-PCR results, we performed Western blot analysis to detect the AML1/ETO fusion protein. Samples from seven of the eight patients with masked t (8:21) shown by RT-PCR were available for Western blot analysis (Table 2) , which showed the AML1/ETO fusion protein in four of the seven 
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Figure 2
Western blot showing AML1/ETO fusion protein (P 1 , P 2 , P 4 and P 5 ) and no detectable fusion transcript protein (P 3 ). All patients were positive for the AML1/ETO fusion transcript as shown by RT-PCR. Extract from cell line Rusumi-1 (C) was used as a positive control. N represents bone marrow from a healthy individual.
(57.1%). Figure 2 shows an example of the Western blot results.
Lack of translocation shown by FISH studies
Using centromeric probes, we were unable to detect translocation of chromosome 8 or 21 in any of the patients showing the AML1/ETO fusion transcript beyond the background level. However, these probes are not specific or sensitive in detecting small translocations that also might not be detectable by the paint probes.
Clinical data and statistical analysis
We identified 21 consecutive patients treated with HDAC who had у2 metaphases showing t(8;21) without any other chromosomal abnormality. The outcomes in these 21 patients, 19 of whom achieved a CR, were compared with those five diploid AML patients with AML1/ETO shown by RT-PCR alone (Table 3 ). Three of those five patients failed to achieve CR despite living more than 6 weeks. The cause of the failure was resistant AML. The remaining two of these five patients achieved a CR. In contrast, the CR rate in the 21 patients with t(8;21) in SC analysis was 90% (P = 0.03). The median CR duration was 20 months. Possible explanations for this difference were that the masked t(8;21) were older and more likely to have antecedent hematological malignancies. Both of these are negative prognostic factors. The differences in survival between the two groups of patients were not statistically significant. The small number of patients in this study makes the statistical analysis difficult to interpret.
Discussion
In this study we attempted to evaluate the prevalence and clinical significance of the molecular counterparts of t (8;21) and inv (16) in AML in patients without those karyotypes on SC analysis. We detected AML1/ETO fusion transcript at a relatively high frequency of 7.7% in patients whose cytogenetic analysis did not show t (8;21) . This result is similar to that observed in the MRC AML trials by Langabeer et al 19 who detected 19 instances of masked t(8;21) among 364 patients (5.2%) not shown by cytogenetic studies. On the contrary, masked CBF␤/MYH11 was not detected in our study. Our results are different from a previously reported study from the MRC, which described 12 cases of masked inv(16) among 300 cases of AML without the chromosomal abnormality shown by standard karyotyping. 20 The reason for this discrepancy is not clear, but it could be due to the smaller number of patients in our study or due to our cytogenetic laboratory usually being alerted to the possibility of inv(16) based on morphology and becoming more careful in searching for this cytogenetic abnormality which is relatively more subtle. This could also suggest that, compared to t(8;21), there is no subpopulation of cells expressing a masked inv (16) . Our experienced cytogenetic laboratory evaluates large numbers of patients with AML, and it is able to identify all inv(16) on standard cytogenetics.
Interestingly, the fusion protein was detected in only 57.1% Performance status Ͼ2 10% (n = 2) 20% (n = 1) 0.49 Antecedent hematological 0% (n = 0) 40% (n = 2) 0.03 disorder Complete remission in 90% (n = 19) 40% (n = 2) 0.03 response to HDAC a Kruskal-Wallis analysis. RT-PCR, reverse transcriptase polymerase chain reaction. Antecedent hematological disorder: any abnormality related to hemoglobin Ͻ12 g/dl, platelets Ͻ100 000 K/Ul or WBC Ͻ5 or Ͼ12 K/Ul for at least 1 month.
of our patients with masked t (8;21) . This is in contrast to the findings in a previous study by Le et al, 21 who detected the AML1/ETO fusion protein in all 10 patients with t(8;21) shown by SC analysis and in Kasumi-1 cell lines. In addition, 40 patients with AML but not the t(8;21) on SC studies showed no AML1/ETO fusion protein. Explanations for this difference include fusion mRNA that is not translated, lack of a stable fusion transcript, or the fusion protein is present in a small proportion of cells or in a concentration below the detectable level.
It is intriguing that patients with diploid AML with molecular evidence of the AML1/ETO transcript differ from patients with conventional t(8;21). Most importantly, the patients with masked t(8;21) have a lower CR rate. Possible explanations include: RT-PCR detection of a clinically irrelevant leukemic clone, detection of a small group of cells that harbor other molecular abnormalities that render them more aggressive, and patients without the cytogenetically detected t(8;21) may not be as sensitive to HDAC. Older age and history of antecedent hematological disorders in the patients with diploid AML may contribute to the disparate clinical outcomes. Also, two of the three diploid patients with positive RT-PCR for AML1/ETO who failed to achieve CR had a higher white blood cell count which is associated with poorer survival. 22 Additional studies are therefore needed to confirm these results and to elucidate the mechanisms underlying this observation. However, despite the differences in both groups, our data indicates that patients with only RT-PCR evidence of t(8;21) should not a priori be regarded as equivalent to those with cytogenetic evidence of t(8;21).
